Lunit has signed a contract for a validation trial of its Insight MMG software to be used in Australia's breast cancer screening program.
The BreastScreen New South Wales (BSNSW) program will first seek to validate Lunit's MMG breast cancer screening tool to confirm its potential clinical benefits prior to integrating it. This validation process will consist of using Insight MMG to analyze approximately 650,000 mammograms and comparing the results to historical reports delivered by BSNSW radiologists, according to the company.
Next, the software's impact on workflow will be assessed over an eight-month period that will include 240,000 exams. In the third phase, the software will be deployed to assist radiologists with all breast screening exams for a year.
Upon successful completion of all phases, Lunit will secure a five-year operational contract with BSNSW, the company said.
